Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 1
2008 1
2013 1
2014 6
2015 5
2016 4
2017 2
2018 7
2019 7
2020 5
2021 11
2022 8
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Trial of Vaccines for Zaire Ebola Virus Disease.
PREVAC Study Team; Kieh M, Richert L, Beavogui AH, Grund B, Leigh B, D'Ortenzio E, Doumbia S, Lhomme E, Sow S, Vatrinet R, Roy C, Kennedy SB, Faye S, Lees S, Millimouno NP, Camara AM, Samai M, Deen GF, Doumbia M, Espérou H, Pierson J, Watson-Jones D, Diallo A, Wentworth D, McLean C, Simon J, Wiedemann A, Dighero-Kemp B, Hensley L, Lane HC, Levy Y, Piot P, Greenwood B, Chêne G, Neaton J, Yazdanpanah Y. PREVAC Study Team, et al. N Engl J Med. 2022 Dec 29;387(26):2411-2424. doi: 10.1056/NEJMoa2200072. Epub 2022 Dec 14. N Engl J Med. 2022. PMID: 36516078 Clinical Trial.
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19.
Ford ES, Mayer-Blackwell K, Jing L, Laing KJ, Sholukh AM, St Germain R, Bossard EL, Xie H, Pulliam TH, Jani S, Selke S, Burrow CJ, McClurkan CL, Wald A, Greninger AL, Holbrook MR, Eaton B, Eudy E, Murphy M, Postnikova E, Robins HS, Elyanow R, Gittelman RM, Ecsedi M, Wilcox E, Chapuis AG, Fiore-Gartland A, Koelle DM. Ford ES, et al. Among authors: postnikova e. Nat Immunol. 2024 Jan;25(1):166-177. doi: 10.1038/s41590-023-01692-x. Epub 2023 Dec 6. Nat Immunol. 2024. PMID: 38057617
Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses.
Ithinji DG, Buchholz DW, Ezzatpour S, Monreal IA, Cong Y, Sahler J, Bangar AS, Imbiakha B, Upadhye V, Liang J, Ma A, Bradel-Tretheway B, Kaza B, Yeo YY, Choi EJ, Johnston GP, Huzella L, Kollins E, Dixit S, Yu S, Postnikova E, Ortega V, August A, Holbrook MR, Aguilar HC. Ithinji DG, et al. Among authors: postnikova e. NPJ Vaccines. 2022 Dec 17;7(1):166. doi: 10.1038/s41541-022-00588-5. NPJ Vaccines. 2022. PMID: 36528644 Free PMC article.
On-Demand Patient-Specific Phenotype-to-Genotype Ebola Virus Characterization.
Beitzel BF, Radoshitzky SR, Di Paola N, Brannan JM, Kimmel D, Caviness K, Soloveva V, Yu S, Postnikova EN, Finch CL, Liu H, Prugar L, Bakken R, Dye JM, Kugelman JR, Cunningham JM, Sanchez-Lockhart M, Kuhn JH, Palacios G. Beitzel BF, et al. Among authors: postnikova en. Viruses. 2021 Oct 6;13(10):2010. doi: 10.3390/v13102010. Viruses. 2021. PMID: 34696439 Free PMC article.
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.
Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J. Cho H, et al. Among authors: postnikova e. bioRxiv [Preprint]. 2021 Apr 1:2021.04.01.437942. doi: 10.1101/2021.04.01.437942. bioRxiv. 2021. PMID: 33821267 Free PMC article. Updated. Preprint.
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants.
Chen Z, Zhang P, Matsuoka Y, Tsybovsky Y, West K, Santos C, Boyd LF, Nguyen H, Pomerenke A, Stephens T, Olia AS, Zhang B, De Giorgi V, Holbrook MR, Gross R, Postnikova E, Garza NL, Johnson RF, Margulies DH, Kwong PD, Alter HJ, Buchholz UJ, Lusso P, Farci P. Chen Z, et al. Among authors: postnikova e. Cell Rep. 2022 Nov 1;41(5):111528. doi: 10.1016/j.celrep.2022.111528. Epub 2022 Sep 30. Cell Rep. 2022. PMID: 36302375 Free PMC article.
Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.
Monteil V, Eaton B, Postnikova E, Murphy M, Braunsfeld B, Crozier I, Kricek F, Niederhöfer J, Schwarzböck A, Breid H, Devignot S, Klingström J, Thålin C, Kellner MJ, Christ W, Havervall S, Mereiter S, Knapp S, Sanchez Jimenez A, Bugajska-Schretter A, Dohnal A, Ruf C, Gugenberger R, Hagelkruys A, Montserrat N, Kozieradzki I, Hasan Ali O, Stadlmann J, Holbrook MR, Schmaljohn C, Oostenbrink C, Shoemaker RH, Mirazimi A, Wirnsberger G, Penninger JM. Monteil V, et al. Among authors: postnikova e. EMBO Mol Med. 2022 Aug 8;14(8):e15230. doi: 10.15252/emmm.202115230. Epub 2022 Jul 4. EMBO Mol Med. 2022. PMID: 35781796 Free PMC article.
Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants.
Chen Z, Zhang P, Matsuoka Y, Tsybovsky Y, West K, Santos C, Boyd LF, Nguyen H, Pomerenke A, Stephens T, Olia AS, De Giorgi V, Holbrook MR, Gross R, Postnikova E, Garza NL, Johnson RF, Margulies DH, Kwong PD, Alter HJ, Buchholz UJ, Lusso P, Farci P. Chen Z, et al. Among authors: postnikova e. medRxiv [Preprint]. 2022 Jan 13:2022.01.12.22269023. doi: 10.1101/2022.01.12.22269023. medRxiv. 2022. PMID: 35043120 Free PMC article. Updated. Preprint.
62 results